Regeneron Stock - Analyst consensus and pipeline backdrop on a quiet news day

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 08:15 UTC. Details in the imprint.

Regeneron (US75886F1075) remains a core name in large-cap biotech, even as the latest trading sessions passed without a major new headline or regulatory filing. With no fresh company news, investors are leaning on the existing analyst consensus and the company’s established business model for orientation.

What recent trading shows

Regeneron shares last closed at $609.94 on 06/18/2026 on Nasdaq, according to recent quote data summarizing the regular session and extended trading that evening. MarketBeat lists the 06/18/2026 close and after-hours levels.

Intraday ranges have been relatively contained, with some trading services showing a 24-hour band roughly between just under $600 and the mid-$610s, highlighting a period of muted volatility rather than sharp swings. A recent REGN quote page displays this narrow 24-hour range.

Analyst views and earnings outlook

Without new company-specific headlines, the analyst consensus acts as the main reference point. Major Wall Street houses continue to cover Regeneron, focusing on revenue drivers such as Eylea and the company’s newer antibody therapies, with a spread of Buy and Hold ratings across the street based on recent aggregated data. A consensus overview compiles the latest ratings and targets.

For upcoming quarterly results later this year, analysts generally expect stable to modestly growing revenue, driven by ophthalmology and immunology franchises, and they remain attentive to any margin effects from pipeline investments and pricing dynamics in the US market.

How the company makes money

Regeneron generates most of its revenue from branded prescription medicines, led by the eye therapy Eylea for neovascular age-related macular degeneration and other retinal diseases, as well as the anti-inflammatory antibody Dupixent, which it co-develops and shares economically with Sanofi.

Where the stock trades today

The shares of Regeneron (US75886F1075) trade on Nasdaq at $610.04 as of 06/20/2026, 08:10 UTC.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.